NICE snubs Orencia, picks 3 rivals

It's final: Britain's National Health Service won't pay for Bristol-Myers Squibb's anti-arthritis drug Orencia. Patient advocacy groups had been lobbying the National Institute for Health and Clinical Excellence to reconsider its earlier recommendation to pass over the drug because it's too expensive.

Meanwhile, NICE recommended Abbott Laboratories' Humira, Amgen's Embrel, and Johnson & Johnson's Remicade for treatment-resistant arthritis. Individual patients will be monitored every six months to make sure the drugs are working; if not, they'll be discontinued.

-read the news release from NICE (pdf)
-read NICE's guidance at its website
-read the story in The Guardian
-read more in the Independent

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.